Bank of Montreal Can cut its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 75.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 170,681 shares of the company's stock after selling 538,302 shares during the period. Bank of Montreal Can owned about 0.37% of Omnicell worth $7,599,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after buying an additional 699,925 shares during the period. Victory Capital Management Inc. grew its stake in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after purchasing an additional 377,883 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Omnicell by 46.1% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company's stock valued at $19,130,000 after buying an additional 135,650 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in shares of Omnicell during the fourth quarter worth about $5,372,000. Finally, ExodusPoint Capital Management LP grew its holdings in shares of Omnicell by 120.5% in the 4th quarter. ExodusPoint Capital Management LP now owns 88,974 shares of the company's stock worth $3,961,000 after acquiring an additional 48,623 shares during the period. Institutional investors and hedge funds own 97.70% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on OMCL shares. JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Benchmark restated a "buy" rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. Finally, Wells Fargo & Company reduced their target price on Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Omnicell presently has an average rating of "Hold" and an average target price of $50.67.
Check Out Our Latest Stock Report on OMCL
Omnicell Trading Down 2.2 %
Shares of NASDAQ:OMCL traded down $0.68 during trading on Thursday, reaching $30.27. The stock had a trading volume of 513,838 shares, compared to its average volume of 531,547. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The stock has a market cap of $1.42 billion, a P/E ratio of 112.10, a PEG ratio of 7.53 and a beta of 0.78. The business has a fifty day moving average price of $35.74 and a 200-day moving average price of $41.45. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.
Omnicell Profile
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
